Home › Research › TREM2 and immune genetics
Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease
Gouilly D, Da-Costa A, Vrillon A, Pistono A, Goubeaud M, Bertrand E, Germain J, Ainaoui N et al.. Journal of neuroinflammation, 2025-11-24
Topic: Brain proteins, microglia and lab models
Plain-language summary
Neuro-inflammation was not reduced between the neflamapimod and placebo groups, and no change was observed in [18F]-DPA-714 PET. However, neflamapimod induced a significant increase in CSF GFAP levels compared to placebo. Multivariate analyses based on CSF biomarkers highlighted the contribution of sTREM2 in the pattern of variation that discriminated the two groups (accuracy = 71%). Patients who received neflamapimod and had baseline sTREM2 level above the median had the highest increase in GFAP compared to placebo, suggesting that neflamapimod may exacerbate reactive astrogliosis as a function of the TREM2-related microglial state. Safety analysis showed that three cases of CSF pleocytosis occurred during follow-up in participants receiving neflamapimod. Neflamapimod at a dose of 40 mg twice-daily interfered with mechanisms of immune defense in early AD. Although this study is exploratory, our results may provide an explanation for the failure of previous anti-inflammatory interventions in early AD. Biomarkers of neuro-inflammation should be required in the next-generation trials targeting neuro-immune mechanisms in AD. REGISTRY: ClinicalTrials.gov, Clinical Trial registration number: NCT03435861.
What this study adds
Evidence grade: High
This is a trial of 17 participants. In this exploratory trial in early Alzheimer's, the anti-inflammatory drug neflamapimod (40 mg twice-daily) did not reduce brain inflammation on PET scans and instead raised spinal fluid GFAP, a marker of reactive astrocytes (support cells). Three cases of spinal fluid inflammation (pleocytosis) occurred on the drug.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gouilly, D., Da-Costa, A., Vrillon, A., Pistono, A., Goubeaud, M., Bertrand, E., et al. (2025). Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease. Journal of neuroinflammation. https://doi.org/10.1186/s12974-025-03625-x
Vancouver
Gouilly D, Da-Costa A, Vrillon A, Pistono A, Goubeaud M, Bertrand E, et al. Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease. Journal of neuroinflammation. 2025. doi:10.1186/s12974-025-03625-x. PMID: 41287056.
BibTeX
@article{gouilly2025-41287056,
author = {Gouilly, D. and Da-Costa, A. and Vrillon, A. and Pistono, A. and Goubeaud, M. and Bertrand, E. and Germain, J. and Ainaoui, N. and others},
title = {{Inhibition of p38α MAPK increases short-term astrocyte reactivity: the exploratory VIP trial in early Alzheimer's disease}},
journal = {Journal of neuroinflammation},
year = {2025},
doi = {10.1186/s12974-025-03625-x},
pmid = {41287056},
url = {https://doi.org/10.1186/s12974-025-03625-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Neuro-inflammation was not reduced between the neflamapimod and placebo groups, and no change was observed in [18F]-DPA-714 PET.
- However, neflamapimod induced a significant increase in CSF GFAP levels compared to placebo.
- Multivariate analyses based on CSF biomarkers highlighted the contribution of sTREM2 in the pattern of variation that discriminated the two groups (accuracy = 71%).
- Patients who received neflamapimod and had baseline sTREM2 level above the median had the highest increase in GFAP compared to placebo, suggesting that neflamapimod may exacerbate reactive astrogliosis as a function of the TREM2-related microglial state.
- Safety analysis showed that three cases of CSF pleocytosis occurred during follow-up in participants receiving neflamapimod.
Why it matters
In this exploratory trial in early Alzheimer's, the anti-inflammatory drug neflamapimod (40 mg twice-daily) did not reduce brain inflammation on PET scans and instead raised spinal fluid GFAP, a marker of reactive astrocytes (support cells). Three cases of spinal fluid inflammation (pleocytosis) occurred on the drug. The authors suggest it interfered with immune defence, which may help explain why earlier anti-inflammatory approaches failed, and urge inflammation biomarkers in future trials.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designrandomized controlled trial
- Participants17
- Evidence strengthHigh
How this study scored 59/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neuroinflammation) |
| Journal's citation record | 2 / 4 | Journal of Neuroinflammation: journal h-index 216 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 17 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jérémie Pariente: h-index 52 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 14 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41287056) |
| Free to read | 2 / 2 | Free to read |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s12974-025-03625-x
- PubMed: 41287056
- Original source →
- Free full text: Journal of Neuroinflammation →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 33.
Related studies in TREM2 and immune genetics from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.